Cipla jumps on receiving USFDA`s approval for Lenalidomide Capsule
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Cipla is currently trading at Rs. 1058.60, up by 17.90 points or 1.72% from its previous closing of Rs. 1040.70 on the BSE.
The scrip opened at Rs. 1038.10 and has touched a high and low of Rs. 1061.55 and Rs. 1035.10 respectively. So far 48969 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1083.15 on 15-Mar-2022 and a 52 week low of Rs. 850.00 on 17-Dec-2021.
Last one week high and low of the scrip stood at Rs. 1061.55 and Rs. 1011.60 respectively. The current market cap of the company is Rs. 84222.13 crore.
The promoters holding in the company stood at 33.61%, while Institutions and Non-Institutions held 48.98% and 17.40% respectively.
Cipla has received final approval for its Abbreviated New Drug Application (ANDA) for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the United States Food and Drug Administration (USFDA). Cipla’s Lenalidomide Capsules are AB-rated therapeutic equivalent generic version of Bristol Myers Squibb’s (Celgene) Revlimid (Lenalidomide) Capsules.
Lenalidomide is an immunomodulatory prescription drug which is indicated for several hematological malignancies in adults such as Multiple Myeloma, Myelodysplastic syndromes, Mantle cell lymphoma, Follicular lymphoma, and Marginal Zone lymphoma. Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings.
Lenalidomide capsules are not to be used in pregnant women. It is not known if lenalidomide is safe and effective in children. Lenalidomide Capsules should not be used to treat people with chronic lymphocytic leukemia (CLL) outside of a controlled clinical trial.
According to IQVIA (IMS Health), Revlimid (Lenalidomide) Capsules had US sales of approximately $ 2.58 billion for the 12-month period ending June 2022. The product will be available for shipping soon.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
